Synthesis, crystal structure and antiproliferative evaluation of some new substituted benzothiazoles and styrylbenzothiazoles

The multistep synthesis of a series of new substituted-benzothiazoles as hydrochloride or quaternary salts is described. 6-Amidino substituted 2-aminobenzothiazoles ( 5, 6), N-methyl-2-(4-cyanostyryl)benzothiazolium iodide ( 8), cyano-substituted-2-styrylbenzothiazoles ( 9-11) and amidino and bis-am...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Farmaco (Società chimica italiana : 1989) 2004-04, Vol.59 (4), p.297-305
Hauptverfasser: Ćaleta, I., Grdiša, M., Mrvoš-Sermek, D., Cetina, M., Tralić-Kulenović, V., Pavelić, K., Karminski-Zamola, G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The multistep synthesis of a series of new substituted-benzothiazoles as hydrochloride or quaternary salts is described. 6-Amidino substituted 2-aminobenzothiazoles ( 5, 6), N-methyl-2-(4-cyanostyryl)benzothiazolium iodide ( 8), cyano-substituted-2-styrylbenzothiazoles ( 9-11) and amidino and bis-amidino-substituted 2-styrylbenzothiazoles ( 12-17) were prepared. The crystal structure of amidino derivative ( 6) was determined by single crystal X-ray analysis. All new prepared compounds were tested on the cytostatic activities against malignant cell lines: (SW620, colon carcinoma; Hep2, laryngeal carcinoma; HBL, melanoma; HeLa, cervical carcinoma and WI38, human normal fibroblasts). The compounds exerted a different inhibitory effect, depended on concentration and type of the cells. The best inhibitory effect was achieved with compounds ( 12-15), with slight differences among them. All of them inhibited the growth of examined tumor cell lines and also normal fibroblasts. Other examined compounds exhibited a moderate inhibitory effect, depending on type of the cells. Majority of them inhibited the growth of HeLa cells and WI38.
ISSN:0014-827X
1879-0569
DOI:10.1016/j.farmac.2004.01.008